AXSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the investor's long-term strategy, beginner level, and available capital, Axsome Therapeutics Inc. (AXSM) is a good buy. Despite short-term technical weakness, the company's strong revenue growth, promising pipeline, and positive analyst sentiment make it a solid long-term investment opportunity.
The stock is currently oversold with an RSI of 13.861, indicating a potential rebound opportunity. However, the MACD is negatively expanding at -3.194, and the price is below the pivot support level of 164.566, showing short-term bearish momentum.
Strong Q4 revenue growth of 65% YoY.
Positive analyst sentiment with multiple price target increases, including UBS ($251), RBC Capital ($222), and Guggenheim ($220).
Promising pipeline with AXS-05 expected to gain FDA approval for Alzheimer's disease agitation, potentially adding $1.6B in market opportunity.
Net income dropped significantly (-61.88% YoY), and EPS declined (-63.64% YoY).
Short-term technical indicators suggest bearish momentum.
Competitive pressure from Helus Pharma's SPL026 in the treatment-resistant depression market.
In Q4 2025, revenue increased by 65.03% YoY to $196M, demonstrating strong growth. However, net income dropped to -$28.56M (-61.88% YoY), and EPS fell to -$0.56 (-63.64% YoY). Gross margin improved to 92.89%, up 3.45% YoY.
Analysts are highly optimistic, with multiple price target increases and ratings such as Buy and Outperform. Price targets range from $202 to $251, reflecting confidence in the company's growth potential and pipeline.
